Adamax

Adamax is a synthetic neuropeptide combining the N-acetyl Semax backbone with an adamantyl modification derived from P21, another BDNF-potentiating nootropic. Developed within the Russian neuropeptide research tradition, Adamax is considered the most potent Semax derivative. The adamantyl (adamantane) group enhances lipophilicity, protects the peptide from enzymatic degradation, extends its half-life, and facilitates blood-brain barrier penetration.

Adamax crosses the blood-brain barrier through enhanced lipophilicity conferred by the adamantyl group, which also protects the peptide from peripheral peptidase degradation. Once in the CNS, Adamax upregulates brain-derived neurotrophic factor (BDNF) expression and enhances the sensitivity of TrkB receptors in the hippocampus — the primary receptor for BDNF signaling. It also modulates dopamine, norepinephrine, and serotonin neurotransmitter systems. The result is enhanced neuroplasticity and improved signal efficiency in circuits underlying working memory, attention, and executive function.

Adamax has been commercially available for roughly two years as of 2026. No independent peer-reviewed clinical trials have been published. All available benefit data are anecdotal reports from users describing improvements in focus, memory consolidation, and complex task performance. Preclinical data on parent compounds Semax and P21 provide mechanistic plausibility. Because Adamax is a novel research compound, safety data, dose-response curves, and long-term effects are uncharacterized.

Peptides commonly paired with Adamax for synergistic effects.